JAMA Cardiol

Self-administered etripamil reduces ED visits in supraventricular tachycardia

April 28, 2025

Study details: This secondary analysis of the phase 3 NODE-301 trial evaluated the use of emergency care after self-administration of etripamil by patients experiencing paroxysmal supraventricular tachycardia (PSVT) episodes at home. The study involved 340 patients who were randomly assigned to receive either etripamil or placebo during PSVT episodes.

Results: Pooled analysis showed that 13.6% of patients who self-administered etripamil required an ED visit compared with 22.4% of those who received placebo, demonstrating an 8.8% absolute risk reduction and a 39% relative risk reduction. Etripamil was nearly twice as likely as placebo to terminate PSVT episodes within 30 minutes, with no serious adverse events reported.

Clinical impact: Self-administered etripamil significantly reduces the need for emergency care in patients with PSVT, offering a promising outpatient treatment option.

Source:

Pokorney SD, et al. (2025, April 9). JAMA Cardiol. Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia: A Secondary Analysis of a Randomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC11983288/